Scientists at the UW Carbone Cancer Center are in human trial phase for a vaccine to treat aggressive forms of prostate cancer.
Scientists say this vaccine, combined with another drug, will help the body target prostate cancer cells.
“We believe this vaccine has the potential to train a patient who has prostate cancer, to train their immune system to recognize the tumors that are growing as foreign and to begin to clear them and remove them from the body,” said Dr. Richard Lesniewski, the president and CEO of Madison Vaccines.
Read the article.